Recent Pfizer Press Releases

  • 4/19/18 12:38 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 9:00 a.m. (Eastern Daylight Time) on Thursday, April 26, 2018. To pre-register and access the live audio webcast, visit https://investors.pfizer.com/proxy and click on the “Annual Meeting Webcast” button. Pre-registration begins today. A replay of the webcast will be available on www.pfizer.com through the firstmore...
  • 4/12/18 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). The first boy received an infusion of the mini-dystrophin gene on March 22nd, administered under the supervision of principal investigator, Edward Smith, MD, Associate Professor of Pediatrics and Neurology at Duke University Medical Center. Screening and enrollment of patients ismore...
  • 4/10/18 2:00 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that the independent Data Monitoring Committee for the Phase 3 ATLAS trial evaluating INLYTA® (axitinib) as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy recommended stopping the trial at a planned interim analysis due to futility. The recommendation was based on the study failing to demonstrate a clear improvement in the primary endpoint of extending disease-freemore...
  • 4/10/18 8:30 am EDT

    Donates $500,000 to Hudson Guild

    NEW YORK--(BUSINESS WIRE)--Pfizer announced that it has signed a 20-year lease for The Spiral, an office tower being built by Tishman Speyer, at 66 Hudson Boulevard at Hudson Yards of Manhattan. As part of its 20-year lease agreement, Pfizer will relocate its global headquarters from 235 East 42nd Street to The Spiral where it will occupy 15 floors, and expects to begin moving colleagues there in 2022. “Pfizer’s history in New York City began in 1849, and we aremore...
  • 4/4/18 8:00 am EDT

    FDA Priority Review Granted for U.S. New Drug Application

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application and granted priority review for dacomitinib, a pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations. The European Medicines Agency has also accepted themore...
  • 4/3/18 8:00 am EDT

    Creates alliance with Allogene Therapeutics, a biotechnology company co-founded and led by former executives of Kite Pharma that is positioned to expedite the development of allogeneic CAR T cell therapy

    Allogene Therapeutics, a Two River portfolio company, was formed with one of the largest Series A financings in biotechnology of $300 million from a premier investment consortium that includes TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer and Pfizer

    Pfizer will hold a 25 percent ownership stake in Allogene Therapeutics

    NEW YORK & SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Allogene Therapeutics, Inc. (Allogene) today announced that the two companies have entered into an asset contribution agreement for Pfizer’s portfolio of assets related to allogeneic chimeric antigen receptor T cell (CAR T) therapy, an investigational immune cell therapy approach to treating cancer. Allogene, co-founded and led by former executives of Kite Pharma, is ideally positioned to catalyze themore...
  • 3/29/18 12:45 pm EDT

    Tafamidis Demonstrated a Statistically Significant Reduction in the Combination of All-cause Mortality and Frequency of Cardiovascular-related Hospitalizations in Global Trial

    Currently, There are No Approved Pharmacological Medications Specifically Indicated for Treating Transthyretin Cardiomyopathy

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study evaluating tafamidis for the treatment of transthyretin cardiomyopathy met its primary endpoint, demonstrating a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo at 30 months. The preliminary safety data showed that tafamidis wasmore...
  • 3/23/18 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today results from a Phase 4 study evaluating the efficacy and safety of CHANTIX®/CHAMPIX® (varenicline) for smoking cessation in nicotine dependent adolescents 12-19 years of age. The study did not meet its primary endpoint of the four-week continuous abstinence rate at weeks 9 through 12 for CHANTIX/CHAMPIX compared to placebo. The study is a regulatory post marketing commitment for CHANTIX/CHAMPIX in the U.S.more...
  • 3/20/18 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 1, 2018. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/more...
  • 3/19/18 4:15 pm EDT

    sNDA Seeks to Expand the Indication of XTANDI to include Men with Non-metastatic CRPC

    NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) has been accepted for filing and granted Priority Review designation by the U.S. Food and Drug Administration (FDA). If approved, the sNDA would expand the indication of XTANDI to include men with non-metastatic Castration-Resistant Prostatemore...